ExchangeDEX+
Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
Alex Tzoukas joins Epikast’s Board of Directors Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos NEW YORK and ATHENS, Greece, Jan. 30, 2026Alex Tzoukas joins Epikast’s Board of Directors Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos NEW YORK and ATHENS, Greece, Jan. 30, 2026

Kos Biotechnology Partners Announces Inaugural Investment, Leads Epikast’s Financing Round

Author: AI JournalSource: AI Journal
2026/01/31 02:30
  • Alex Tzoukas joins Epikast’s Board of Directors
  • Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos

NEW YORK and ATHENS, Greece, Jan. 30, 2026 /PRNewswire/ — Kos Biotechnology Partners (“Kos”), a global life sciences investment firm, today announced the closing of a financing round in Epikast, a premier provider of technology-enabled commercial and clinical services for the biopharmaceutical industry. This transaction marks the first investment from Kos’ inaugural fund, which is focused on a broad range of investment stages, including the seeding and scaling of high-impact life sciences platforms.

Kos led the round with significant participation from a syndicate of new and existing investors. In conjunction with the financing, Alex Tzoukas, Managing Partner and Co-Founder at Kos, will join Epikast’s Board of Directors.

The capital infusion will enhance Epikast’s proprietary technology platform and the scaling of its specialized service teams. Epikast bridges the gap between high-level medical expertise and cost-efficient operations by leveraging its Greece-based operational hub to serve global biopharmaceutical clients.

Alex Tzoukas, Managing Partner and Co-Founder of Kos Biotechnology Partners commented: “Epikast represents an exciting investment for our new fund. The company has developed a differentiated, tech-enabled pharma services model that addresses a clear inefficiency in how biopharma companies engage with healthcare providers and patients. We are pleased to lead this round and support the company as it scales.”

Dr. Stelios Papadopoulos, Chairman of Epikast, added: “We are pleased to welcome Kos Biotechnology Partners as lead investor in this round. Kos brings deep sector expertise and a strong connection to both the US and Greek innovation ecosystems, which aligns well with Epikast’s operating model. Alex’s addition to the board adds valuable perspective as we enter the next phase of growth.”

Dr. Simos Simeonidis, Managing Partner and Co-Founder of Kos Biotechnology Partners commented: “We are pleased to partner with Stelios and his team at Epikast with the first investment from our fund. Alex’s deep background as a life sciences investor, investment banker, and operator will further enhance the strong expertise already present on Epikast’s Board.”

Dr. Vangelis Vergetis, CEO of Epikast, concluded: “This financing reinforces Epikast’s strong momentum. We place a premium on partnering with individuals who bring deep expertise and strong judgment. Alex Tzoukas, Simos Simeonidis, and Nikos Kostaras exemplify that and will be valuable partners as we advance our next phase.”

About Epikast

Epikast is a technology-enabled biopharmaceutical services company headquartered in New York with core operations in Athens, Greece. The company provides a comprehensive suite of remote commercial, medical, market access, and patient support services. By combining highly trained medical professionals with a proprietary technology stack, Epikast delivers high-quality engagement and data-driven insights to biopharma clients at a significantly optimized cost structure. It currently partners with several global top 10 pharma companies and smaller biotechnology companies as they commercialize their products in the US and Europe.

About Kos Biotechnology Partners

Kos Biotechnology Partners is a global investment firm founded in 2025 by Dr. Simos Simeonidis and Alex Tzoukas, with a focus on identifying, supporting, and scaling innovative, high-potential opportunities in the life sciences sector. With the launch of its inaugural fund, Kos partners with experienced management teams to build enduring products, services, and platforms through strategic capital, deep operational expertise, and a long-term perspective on value creation.

Media Contacts: info@kosbp.com, info@epikast.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kos-biotechnology-partners-announces-inaugural-investment-leads-epikasts-financing-round-302675286.html

SOURCE Kos Biotechnology Partners

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

What is the 80 20 rule for Airbnb? A practical guide for hosts

What is the 80 20 rule for Airbnb? A practical guide for hosts

This article explains the 80 20 idea as a practical heuristic for Airbnb hosts and shows how it links to realistic, low-cash ways people gain control of short-term
Share
Coinstats2026/01/31 08:42
Tokenized Assets Shift From Wrappers to Building Blocks in DeFi

Tokenized Assets Shift From Wrappers to Building Blocks in DeFi

The post Tokenized Assets Shift From Wrappers to Building Blocks in DeFi appeared on BitcoinEthereumNews.com. RWAs are rapidly moving on-chain, unlocking new opportunities for investors and DeFi protocols, according to a new report from Dune and RWAxyz. Tokenized real-world assets (RWAs) are moving beyond digital versions of traditional securities to become key building blocks of decentralized finance (DeFi), according to the 2025 RWA Report from Dune and RWAxyz. The report notes that Treasuries, bonds, credit, and equities are now being used in DeFi as collateral, trading instruments, and yield products. This marks tokenization’s “real breakthrough” – composability, or the ability to combine and reuse assets across different protocols. Projects are already showing how this works in practice. Asset manager Maple Finance’s syrupUSDC, for example, has grown to $2.5 billion, with more than 30% placed in DeFi apps like Spark ($570 million). Centrifuge’s new deJAAA token, a wrapper for Janus Henderson’s AAA CLO fund, is already trading on Aerodrome, Coinbase and other exchanges, with Stellar planned next. Meanwhile, Aave’s Horizon RWA Market now lets institutional users post tokenized Treasuries and CLOs as collateral. This trend underscores a bigger shift: RWAs are no longer just copies of traditional assets; instead, they are becoming core parts of on-chain finance, powering lending, liquidity, and yield, and helping to close the gap between traditional finance (TradFi) and DeFi. “RWAs have crossed the chasm from experimentation to execution,” Sid Powell, CEO of Maple Finance, says in the report. “Our growth to $3.5B AUM reflects a broader shift: traditional financial services are adopting crypto assets while institutions seek exposure to on-chain markets.” Investor demand for higher returns and more diversified options is mainly driving this growth. Tokenized Treasuries proved there is strong demand, with $7.3 billion issued by September 2025 – up 85% year-to-date. The growth was led by BlackRock, WisdomTree, Ondo, and Centrifuge’s JTRSY (Janus Henderson Anemoy Treasury Fund). Spark’s $1…
Share
BitcoinEthereumNews2025/09/18 06:10
Why ZKP Ranks Among the Best New Cryptos to Buy With Fair Design and Private Compute

Why ZKP Ranks Among the Best New Cryptos to Buy With Fair Design and Private Compute

While many investors focus on the latest trending tokens, ZKP has been steadily building a foundation with lasting value. By combining real hardware, verifiable
Share
Techbullion2026/01/31 09:00